Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2

被引：5
|
作者：
Armstrong, A. [1 ]
Eyerich, K. [2 ]
Conrad, C. [3 ]
Zhu, Y. [4 ]
Yang, Y. -w. [5 ]
Miller, M. [4 ]
You, Y. [4 ]
Shen, Y. -k. [4 ]
Foley, P. [6 ]
Griffiths, C. E. M. [7 ,8 ]
Strober, B. [9 ,10 ,11 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[2] Univ Freiburg, Baden Wurttemberg, Germany
[3] Lausanne Univ Hosp CHUV, Lausanne, Switzerland
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
[6] Univ Melbourne, St Vincents Hosp Melbourne & Prob Med Res, Skin Hlth Inst, Carlton, Vic, Australia
[7] Univ Manchester, Dermatol Ctr, NIHR Manchester Biomed Res Ctr, Manchester, England
[8] Kings Coll London, Kings Coll Hosp, London, England
[9] Yale Univ, New Haven, CT USA
[10] Cent Connecticut Dermatol Res, Cromwell, CT USA
[11] Cent Connecticut Dermatol Res, 1 Willowbrook Rd, Cromwell, CT 06416 USA
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 12期
关键词：
PHASE-III; THERAPY;
D O I：
10.1111/jdv.19309
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E1375 / E1379
页数：5
相关论文
共 50 条
  • [1] Immunogenicity of Guselkumab among psoriasis patients in VOYAGE 1 and VOYAGE 2
    Reich, K.
    Armstrong, A. W.
    Zhu, Y.
    Miller, M.
    You, Y.
    Shen, Y. -K.
    Yang, Y. W.
    Foley, P.
    Griffiths, C. E. M.
    Strober, B.
    [J]. EXPERIMENTAL DERMATOLOGY, 2021, 30 : 42 - 42
  • [2] EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS
    Gordon, K.
    Merola, J. F.
    Foley, P.
    Choi, O.
    Chan, D.
    Miller, M.
    You, Y.
    Shen, Y. K.
    Yang, Y. W.
    Blauvelt, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1842 - 1842
  • [3] Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies
    Gordon, K. B.
    Blauvelt, A.
    Foley, P.
    Song, M.
    Wasfi, Y.
    Randazzo, B.
    Shen, Y. K.
    You, Y.
    Griffiths, C. E. M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (01) : 132 - 139
  • [4] Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies
    Reich, K.
    Papp, K. A.
    Armstrong, A. W.
    Wasfi, Y.
    Li, S.
    Shen, Y. K.
    Randazzo, B.
    Song, M.
    Kimball, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1039 - 1049
  • [5] Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
    Conrad, Curdin
    Koerber, Andreas
    Schaekel, Knut
    Thaci, Diamant
    Joks, Gero
    Jazra, Maria
    Wegner, Sven
    Wapenaar, Robert
    Paul, Carle
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB107 - AB107
  • [6] Characterization of super responders to guselkumab treatment in moderate-to-severe psoriasis: results from the VOYAGE 1 and 2 clinical trials
    Reich, K.
    Gordon, K. B.
    Strober, B.
    Langley, R. G.
    Song, M.
    Shen, Y-K
    You, Y.
    Foley, P.
    Blauvelt, A.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 55 - 56
  • [7] Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis
    Zhu, Yaowei
    Marini, Joseph C.
    Song, Michael
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Li, Shu
    Zhou, Honghui
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (08) : 1830 - 1834
  • [8] Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Lebwohl, Mark
    Langley, Richard G.
    Rowland, Katelyn
    Yang, Ya-Wen
    Chan, Daphne
    Miller, Megan
    You, Yin
    Yu, Jenny
    Thaci, Diamant
    Foley, Peter
    Papp, Kim A.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 274 - 282
  • [9] Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
    Blauvelt, Andrew
    Tsai, Tsen-Fang
    Langley, Richard G.
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Yang, Ya-Wen
    Papp, Kim A.
    Puig, Luis
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (04) : 827 - 834
  • [10] TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL
    Griffiths, C. E.
    Papp, K. A.
    Kimball, A. B.
    Randazzo, B.
    Wasfi, Y.
    Li, S.
    Shen, Y. -K.
    Blauvelt, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1580 - 1581
12345